This listing of claims will replace all prior versions, and listings, of claims in the application:

## **LISTING OF CLAIMS:**

Claim 1 (currently amended): A method for lowering sex hormone levels in an individual a human subject in need of treatment, comprising administering to an individual appropriate doses the subject an effective amount of an LHRH-antagonist, wherein said LHRH-antagonist is peptidic or non-peptidic, wherein and said LHRH-antagonist will lower sex hormone levels in said individual are lowered to a certain extent but not to the point of castration or below the castration level of said individual subject.

Claim 2 (currently amended): A method for lowering sex hormone levels in an individual a human subject in need of treatment, comprising administering appropriate doses to the subject an effective amount of an LHRH-antagonist to an individual said subject wherein the lowered sex hormone levels in said individual subject result in modification of the T-cell population in said individual subject.

Claim 3 (canceled).

Claim 4 (currently amended): A method for lowering sex hormone levels in an individual a human subject in need of treatment, comprising administering appropriate doses to the subject an effective amount of an LHRH-antagonist to an individual said subject

wherein the lowered sex hormone levels in said individual subject result in a modification of the T-cell population in an individual suffering from a HIV infection, cancer, an auto-immune disease, benign prostatic hyperplasia, endometriosis, asthma, arthritis, dermatitis, multiple sclerosis, Jacob Creuzfeldt-disease, or Alzheimer's disease.

Claim 5 (canceled).

Claim 6 (canceled).

Claim 7-11 (withdrawn).

Claim 12 (Currently amended): The method according to any one of claims 1-6, wherein the <u>said</u> LHRH-antagonist is chosen from <del>cetrorelix</del>, teverelix, antide, or abarelix CETRORELIX, TEVERELIX, ANTIDE, or ABARELIX.

Claim 13 (Currently amended): The method according to any one of claims 1-6, wherein the <u>said</u> LHRH-antagonists is <u>cetrorelix</u> <u>CETRORELIX</u> or a pharmaceutically acceptable salt form thereof.

Claim 14 (currently amended): The method according to any one of claims 1-6, wherein the appropriate doses said effective amount of an LHRH-antagonist are determined from a total dosage range of is administered at a dose of about 5 mg to 120 mg divided in for a period of ranging from 1 to 8 weeks according to needs of the individual with repeat of the therapy every 3 to 4 months and optionally repeating method of lowering sex hormone levels every 3 to 4 months while there is still a need of treatment by said subject.

Claim 15 (currently amended): The method according to any one of claims 1-6, wherein the LHRH-antagonist eetrorelix pamoate <u>CETRORELIX PAMOATE</u> is administered in a dosage amount determined from a total dosage range of at a dose of about 30 mg to 120 mg divided in <u>for</u> a period of <u>ranging from</u> 1 to 4 weeks according to needs, with repeat of the therapy method every 3 to 4 months as needed and optionally repeating method of lowering sex hormone levels every 3 to 4 months while there is still a need of treatment by said subject

Claim 16 (currently amended): The method according to any one of claims 1-6, wherein the LHRH-antagonist eetrorelix acctate CETRORELIX ACETATE is administered in a dosage amount determined from a total dosage range of in a dose of about 5 mg to 80 mg divided in for a period of ranging from 1 to 8 weeks according to needs, with repeat of the therapy method every 3 to 4 months as needed and optionally repeating method of lowering sex hormone levels every 3 to 4 months while there is still a need of treatment by said subject.